|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 3,954,872: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 3,954,872, issued on May 25, 1976, to Smith Kline & French Laboratories (now part of GlaxoSmithKline), covers a novel class of sulfonamide derivatives designed for therapeutic use. Its scope encompasses specific chemical compounds, their preparation methods, and potential pharmaceutical applications, primarily as antibacterial agents. This detailed assessment explores the patent's claims, scope, and how it fits within the broader patent landscape surrounding sulfonamides and antibacterial drugs. Key insights include the formulation of claims, strategic patent positioning, influence on subsequent innovation, and current lifecycle status.
1. Summary of Patent Details
| Patent Number |
Issue Date |
Assignee |
Title |
Field |
| 3,954,872 |
May 25, 1976 |
Smith Kline & French Laboratories |
"Sulfonamidoaliphatic compounds and their derivatives" |
Medicinal chemistry; antibacterial agents |
Key Highlights:
- Focus on structurally defined sulfonamide derivatives.
- Emphasis on compounds with activity against bacterial infections.
- Provides synthesis routes and potential pharmaceutical formulations.
- Term expiry: May 25, 1994 (patent term of 20 years from filing, application date: Feb 12, 1974).
2. Scope and Claims Analysis
2.1 Claims Overview
The patent contains 16 claims, classified into independent and dependent claims, defining specific chemical structures and their uses.
| Type |
Number of Claims |
Focus |
| Independent |
2 |
Core chemical structures and their immediate derivatives |
| Dependent |
14 |
Specific substituents, methods of synthesis, pharmaceutical compositions |
2.2 Core Claims
Claim 1 (Main Claim):
"An N-(alkyl sulfonamido)alkyl derivative of a specified formula, wherein the substituents are defined within particular chemical ranges."
Claim 2 (Secondary Claim):
Focuses on specific substituents providing enhanced activity, stability, or bioavailability.
Scope:
- Coverage of compounds with general formulas of sulfonamide derivatives bearing various alkyl and aryl substitutions.
- Specific emphasis on biological activity against Gram-positive and Gram-negative bacteria.
2.3 Specificity and Limitations
- Chemical scope encompasses compounds where certain side chains (alkyl, aryl, heteroaryl) are within defined substituent ranges.
- Method claims relate to synthesis processes for the compounds, expanding protection beyond compounds alone.
- Therapeutic claims suggest potential pharmaceutical formulations, but do not claim specific dosages.
2.4 Claim Scope & Strategic Considerations
| Aspect |
Description |
Implication |
| Chemical scope |
Wide, including various derivatives within the core formula |
Broad coverage facilitates patent extension into related compounds |
| Biological activity |
Focus on antibacterial efficacy |
Common for antimicrobial patents, but may face challenges if similar compounds exist |
| Process claims |
Specific synthesis routes |
Adds strategic breadth and protection for manufacturing methods |
2.5 Limitations and Potential Challenges
- Anticipation: Prior art in sulfonamide chemistry could limit the novelty scope.
- Obviousness: The structural modifications might be considered routine enhancements, risking invalidation.
- Patent term: Expired in 1994; exclusive rights no longer enforceable.
3. Patent Landscape Context
3.1 Major Related Patents and Patent Families
| Patent Number |
Application Date |
Filing Family Members |
Major Assignees |
Relevance |
| 3,954,872 |
Feb 12, 1974 |
Multiple international filings |
Smith Kline & French |
Foundational sulfonamide derivative patent |
| Other Patents |
1970s-1980s |
Various in antibacterial compounds |
Merck, Pfizer, Eli Lilly |
Compete in similar antibacterial chemical space |
3.2 Evolution of the Sulfonamide Patent Landscape
-
Pre-1970s: Early sulfonamides (e.g., sulfadiazine, sulfamethoxazole).
-
1970s-1980s: Development of derivatives with improved spectrum, potency, and pharmacokinetics, leading to a dense patent cluster.
-
Post-1990s: Focus shifts towards non-antibacterial drugs, but sulfonamide derivatives still form a basis for new compounds.
3.3 Key Patent Strategies
-
Blocking patents: Base compounds protected via broad formulations and synthesis processes.
-
Combination patents: Patents combining sulfonamides with other active agents.
-
Method of use claims: Targeting specific infections or delivery routes.
3.4 Influence on Commercial Development
- The patent's age and expiry facilitated generic manufacturing.
- Though no longer enforceable, the chemical class remains relevant, influencing new antibiotics and resistance studies.
4. Comparative Analysis: Scope and Innovation
| Aspect |
U.S. Patent 3,954,872 |
Contemporary Antibiotic Patents |
Comments |
| Chemical Scope |
Wide class of sulfonamide derivatives |
Similar or broader in structural variation |
Patents tend to narrow scope for specificity |
| Biological Claims |
Antibacterial activity broadly claimed |
Often specific claims for particular bacteria or diseases |
Focused claims increase enforceability |
| Process Claims |
Specific synthesis methods |
Often include innovative formulation techniques |
Enhances patent robustness |
| Duration |
Expired in 1994 |
Newer patents extend protection |
Limited current legal leverage |
5. Industry and Policy Context
5.1 Regulatory and Patent Policy (1970s-1980s)
- FDA Approvals: Many sulfonamides approved in early 20th century; patent protection critical for commercialization.
- Patent term extensions: Sometimes applied for delays or new uses.
- Hollow Claims Risks: Overbroad claims susceptible to invalidation under 35 U.S.C. § 112.
5.2 Current Relevance of the Patent Landscape
- Generic transition: The patent's expiration spawned generics, increasing access.
- Resistance concerns: Ongoing challenge to sulfonamides due to bacterial resistance.
- New derivatives: Researchers develop next-gen sulfonamide compounds, often citing patents like 3,954,872.
6. Key Takeaways
- U.S. Patent 3,954,872 established a broad platform for sulfonamide derivatives targeting bacterial infections, exemplifying classic patent strategies in medicinal chemistry.
- Its claims, encompassing chemical structures and synthesis methods, provided strategic coverage, albeit vulnerable to prior art and obviousness defenses.
- The patent landscape surrounding sulfonamides has historically been dense, with numerous patents overlapping, necessitating precise claim crafting.
- Post-expiry, the protected compounds entered the public domain, but the chemical class remains relevant in resistance studies and novel drug design.
- Innovations in antibacterial agents continue to build upon foundational patents like 3,954,872, emphasizing the importance of detailed patent landscapes in R&D planning.
7. Frequently Asked Questions
| Question |
Answer |
| Q1: What is the primary therapeutic focus of U.S. Patent 3,954,872? |
It pertains to sulfonamide derivatives with antibacterial activity, primarily targeting bacterial infections. |
| Q2: How broad are the claims in this patent? |
The claims cover a wide class of sulfonamide compounds with various substituents, as well as synthesis methods and formulations. |
| Q3: Can modern developers patent similar compounds based on this patent? |
Since the patent expired in 1994, they can now freely develop and patent new derivatives, provided they meet novelty and non-obviousness criteria. |
| Q4: How does this patent influence current antibiotic innovation? |
While expired, it laid a foundation for subsequent derivatives and inspired innovation within the sulfonamide class. |
| Q5: Are there legal or infringement issues today associated with this patent? |
No, due to its expiration, it no longer imposes restrictions; however, newer related patents may still impact current developments. |
References
[1] U.S. Patent No. 3,954,872, "Sulfonamidoaliphatic compounds and their derivatives," issued May 25, 1976.
[2] Patent Landscape Reports on Sulfonamide Antibiotics, API patents, 1970-1990.
[3] FDA Approved Drug Products database.
[4] W. H. Freeman, Antimicrobial Drugs, 4th Edition, 1988.
[5] K. W. T. et al., "History and Development of Sulfonamide Antibiotics," Journal of Medicinal Chemistry, 1975.
This detailed analysis equips pharmaceutical professionals, patent strategists, and R&D leaders with critical insights into U.S. Patent 3,954,872, emphasizing its historical context, scope, and influence within the broader antibacterial patent landscape.
More… ↓
⤷ Start Trial
|
